论文部分内容阅读
目的:研究浆液性卵巢癌中雌孕激素受体表达的意义及与预后的关系。方法:选取1984.1~2003.7月在我院妇科首次收治的浆液性卵巢癌48例,卵巢浆液性囊腺瘤12例,正常卵巢10例。用SP法测定ER、PR蛋白表达情况,并与临床特征比较。结果:ER、PR阳性染色位于细胞核内,在卵巢癌、良性肿瘤、正常卵巢中ER表达率为27.08%、33.33%、100%,PR表达率为41.67%、83.33%、100%,差异有极显著性(P<0.01)。ER、PR表达与浆液性卵巢癌的生存、分期、病理分级、淋巴关系,经检验差异无显著性(P>0.05)。结论:本研究中PR情况与患者生存情况无关。要明确ER、PR对卵巢癌的意义应作单一病理类型卵巢癌的受体多种测定方法的前瞻性研究。
Objective: To study the significance of estrogen-progesterone receptor expression in serous ovarian cancer and its relationship with prognosis. Methods: Forty-eight cases of serous ovarian cancer, 12 cases of ovarian serous cystadenoma and 10 cases of normal ovary were enrolled in our hospital from 1984.1 to 2003.7. The expression of ER and PR protein was measured by SP method and compared with clinical features. Results: The positive staining of ER and PR was located in the nucleus. The positive rates of ER expression in ovarian cancer, benign tumor and normal ovary were 27.08%, 33.33% and 100%, respectively. The positive rates of PR were 41.67%, 83.33% and 100% Significance (P <0.01). There was no significant difference between the expression of ER, PR and the survival, staging, pathological grade and lymphatic metastasis of serous ovarian cancer (P> 0.05). Conclusion: The PR status in this study has nothing to do with the patient’s survival. To clear ER, PR on the significance of ovarian cancer should be a single pathological type of ovarian cancer receptor assay for a variety of prospective studies.